WE ARE COMING ON THE AIR WITH THE BIG RISK TONIGHT FOR MORE POTENTIALLY DEADLY TORNADOES. AFTER STORMS RIPPED UP TREES AND HOUSES FROM THE GULF TO THE GREAT LAKES. GRAPEFRUIT SIZED HAIL COMING DOWN OVER THE MIDWEST.WE'RE TRACKING THE LATEST THREATS, AND WE'RE LIVE IN INDIANA. PLUS, THAT WEATHER IS MAKING A MESS OF TRAVEL, RIGHT AS HUNDREDS OF TSA OFFICERS WALK OFF THE JOB. ACCORDING TO A SENIOR OFFICIAL.THIS HOMELAND SECURITY SHUTDOWN CREATING PLENTY OF PAIN FOR WORKERS WITHOUT PAY. WE'VE GOT OUR TOM COSTEL ...

[music] Abbott's Freestyle Libre 3 glucose monitors offer diabetics painless readings, blood sugar levels taken not with a finger prick, but a sensor on the arm. The reading sent to a monitor or cell phone. For Devonte Ford, a licensed caregiver, it was a valuable tool attending to his dad, Michael, bed bound by diabetes. >> What are your memories of him dealing with diabetes? >> Always like the finger prick, you know, that was something I always seen him do. So diabetes was just part of his life. >> It was ...

Core Viewpoint - The investigation by Hunterbrook Media highlights significant safety, operational, and financial concerns regarding DexCom, Inc.'s G7 continuous glucose monitor, indicating a decline in the company's reputation and potential risks to patient health [2][5]. Financial Performance - DexCom's share price was $65.41 as of October 15th, with trailing and forward P/E ratios of 46.79 and 25.64 respectively [1]. - Financial indicators suggest deteriorating fundamentals, including a surge in days sales outstanding and a doubling of work-in-process inventory, raising concerns about revenue recognition practices [4]. Product Issues - The G7 sensor's performance has been compromised due to a secret alteration of a key component, leading to underperformance in accuracy metrics and resulting in the FDA classifying the device as "adulterated" [2][3]. - Users have reported serious inaccuracies, leading to hospitalizations and fatalities, including a case linked to a device failure [2][3]. Corporate Culture and Management - Former employees have criticized the corporate culture for prioritizing profit margins over safety, with inadequate technical oversight and rushed design decisions to compete with Abbott's Freestyle Libre 3 [3]. - There are indications of systemic issues within the company, evidenced by executive departures, insider sales, and repeated product recalls [4]. Competitive Landscape - DexCom faces increasing competition from Abbott's superior devices and potential changes in Medicare policies, which could threaten its market share [4]. - The company's own initiatives, such as the Stelo device, are also experiencing accuracy problems and legal challenges [4].